Second quarter total revenue of $147 million, Crysvita® revenue of $114 million and Dojolvi® revenue of $19 million
Increased 2024 expected total revenue guidance to $530 million to $550 million
https://www.biospace.com/ultragenyx-reports-second-quarter-2024-financial-results-and-corporate-update
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.